Larimar Therapeutics/$LRMR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Larimar Therapeutics
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Ticker
$LRMR
Sector
Health
Primary listing
Employees
65
Headquarters
Website
LRMR Metrics
BasicAdvanced
$313M
-
-$1.49
0.91
-
Price and volume
Market cap
$313M
Beta
0.91
52-week high
$8.93
52-week low
$1.61
Average daily volume
1.3M
Financial strength
Current ratio
7.477
Quick ratio
7.165
Long term debt to equity
2.613
Total debt to equity
3.373
Profitability
EBITDA (TTM)
-105.018
Management effectiveness
Return on assets (TTM)
-31.47%
Return on equity (TTM)
-50.77%
Valuation
Price to book
1.62
Price to tangible book (TTM)
1.62
Price to free cash flow (TTM)
-2.673
Free cash flow yield (TTM)
-37.42%
Free cash flow per share (TTM)
-1.369
Growth
Earnings per share change (TTM)
53.22%
3-year earnings per share growth (CAGR)
-17.70%
What the Analysts think about LRMR
Analyst ratings (Buy, Hold, Sell) for Larimar Therapeutics stock.
Bulls say / Bears say
The FDA has signaled support for using skin frataxin concentrations as a surrogate endpoint and provided clear guidance for the nomlabofusp BLA, enabling the company to target accelerated approval by year-end 2025 and derisking the regulatory pathway.
With $157.5 million in cash and marketable securities as of March 31, 2025, and no debt, Larimar is well-capitalized to fund its Phase 3 program and BLA submission through mid-2026 without immediate dilution.
Initiation of coverage by Truist Securities with a Buy rating and an average price target of $21.93 (491% upside), combined with a consensus Buy rating and average target of ~$20.13 from 11 analysts, reflects strong institutional and broker-dealer confidence in Larimar’s long-term prospects
Larimar’s quarterly cash burn has nearly doubled year-over-year, with R&D expenses rising to $26.6 million in Q1 2025, and cash runway extending only into Q2 2026, suggesting the company may need to raise additional capital and dilute shareholders sooner than anticipated.
Key clinical catalysts remain distant, as global Phase 3 initiation is not expected until mid-2025 and topline data from the open-label extension and adolescent PK cohort won’t be available until September 2025, prolonging the period without material news.
Larimar continues to generate no revenue and has posted consecutive EPS misses (Q4 2024 EPS of -$0.45 vs. estimate -$0.29 and Q1 2025 EPS of -$0.46), underscoring its unprofitable profile and reliance on future clinical success
Data summarised monthly by Lightyear AI. Last updated on 22 Jul 2025.
LRMR Financial Performance
Revenues and expenses
LRMR Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Larimar Therapeutics stock?
Larimar Therapeutics (LRMR) has a market cap of $313M as of August 09, 2025.
What is the P/E ratio for Larimar Therapeutics stock?
The price to earnings (P/E) ratio for Larimar Therapeutics (LRMR) stock is 0 as of August 09, 2025.
Does Larimar Therapeutics stock pay dividends?
No, Larimar Therapeutics (LRMR) stock does not pay dividends to its shareholders as of August 09, 2025.
When is the next Larimar Therapeutics dividend payment date?
Larimar Therapeutics (LRMR) stock does not pay dividends to its shareholders.
What is the beta indicator for Larimar Therapeutics?
Larimar Therapeutics (LRMR) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.